Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 ...

Osteogenesis imperfecta (OI) refers to a group of bone disorders in which certain genetic mutations affect the formation of ...

Mereo BioPharma Group plc (NASDAQ:MREO) is one of the Best 52-Week Low Penny Stocks to Buy Now. On July 9, Mereo BioPharma ...

Osteogenesis imperfecta (OI), also known as brittle bone disease, is a rare genetic disease affecting the connective tissue and bones. In this disease, bones become extremely fragile and break or ...

Osteogenesis imperfecta, also known as brittle bone disease, is a genetic disorder that causes bones to break easily. Severe cases of the disease can result in hundreds of fractures during a ...

Osteogenesis imperfecta – also known as brittle bone disorder – is a genetic illness that affects fewer than 50,000 people in the U.S., including Dr. Pamela Smith (pictured).

Osteogenesis imperfecta is a genetic bone disorder causing easily broken bones and deformities. A child born with OI may have soft bones that break (fracture) easily, bones that are not formed ...

Classic osteogenesis imperfecta, an autosomal dominant disorder associated with osteoporosis and bone fragility, is caused by mutations in the genes for type I collagen. A recessive form of the ...

The osteogenesis imperfecta group had a significantly higher Charlson comorbidity index compared with the reference group (P = .003).

Over a mean 17.9 years’ observation, 416 patients with osteogenesis imperfecta experienced 1,566 fractures; median number of fractures was 1 per patient, amounting to 0.15 fractures per person-year.